ZURA 8-K: SEC filing
Zura Bio Limited
Filed with the SEC on · accession 0001104659-26-124149
ZURA filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Zura Bio Limited issued a press release providing a clinical update on its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa.
Key details
✦ Ask GOAX AI about this filing — what it means for ZURA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ZURA?
Click hereFrequently asked questions
What did ZURA file with the SEC on Nov 9, 2026?
ZURA filed a 8-K (SEC filing). Zura Bio Limited issued a press release providing a clinical update on its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other ZURA SEC filings
Get alerts when ZURA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days